New treatment approach for prostate cancer using RNA regulation
Regulation of RNA Decapping and Degradation: A novel approach to prostate cancer therapy
This study is testing a new treatment called VBT-34 that helps fight advanced prostate cancer by speeding up the destruction of harmful RNA in cancer cells, especially for patients who haven't had success with other therapies.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vortex Biotechnology Corporation NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-10758110 on NIH RePORTER |
What this research studies
This research focuses on developing a novel small molecule that regulates RNA destruction to treat prostate cancer, particularly in cases where standard therapies have failed. The approach involves blocking specific proteins that inhibit RNA decapping, which is crucial for the destruction of cancer-related RNAs. By enhancing RNA degradation, the treatment aims to reduce cancer cell growth and invasion, potentially improving outcomes for patients with advanced prostate cancer. The research includes laboratory experiments to test the effectiveness of the new compound, VBT-34, in inhibiting cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who have experienced treatment failure with standard therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone standard treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for men with advanced prostate cancer who have not responded to existing therapies.
How similar studies have performed: While the approach of targeting RNA regulation is innovative, similar strategies in cancer treatment have shown promise, indicating potential for success.
Where this research is happening
Charleston, United States
- Vortex Biotechnology Corporation — Charleston, United States (Active)
Researchers
- Principal investigator: Kraft, Andrew S — Vortex Biotechnology Corporation
- Study coordinator: Kraft, Andrew S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.